ADAP Key Statistics, Chart & Performance
The current stock price of ADAP is 0.0549 USD. In the past month the price decreased by -60.79%. In the past year, price decreased by -93.14%.
ADAP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ADAP
Company Profile
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Company Info
ADAPTIMMUNE THERAPEUTICS-ADR
60 Jubilee Avenue, Milton Park
Abingdon OXFORDSHIRE OX14 4RX GB
CEO: Adrian Rawcliffe
Employees: 506
Phone: 441235430000
ADAPTIMMUNE THERAPEUTICS-ADR / ADAP FAQ
What does ADAP do?
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
What is the stock price of ADAPTIMMUNE THERAPEUTICS-ADR today?
The current stock price of ADAP is 0.0549 USD. The price decreased by -15.15% in the last trading session.
Does ADAPTIMMUNE THERAPEUTICS-ADR pay dividends?
ADAP does not pay a dividend.
How is the ChartMill rating for ADAPTIMMUNE THERAPEUTICS-ADR?
ADAP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock traded?
ADAP stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of ADAP stock?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) operates in the Health Care sector and the Biotechnology industry.
What is ADAPTIMMUNE THERAPEUTICS-ADR worth?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) has a market capitalization of 14.55M USD. This makes ADAP a Nano Cap stock.
ADAP Technical Analysis
ADAP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADAP. Both the profitability and financial health of ADAP have multiple concerns.
ADAP Financial Highlights
Over the last trailing twelve months ADAP reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS decreased by -21.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -129.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADAP Forecast & Estimates
6 analysts have analysed ADAP and the average price target is 0.28 USD. This implies a price increase of 410.93% is expected in the next year compared to the current price of 0.0549.
For the next year, analysts expect an EPS growth of -152.32% and a revenue growth -85.59% for ADAP